Clinical Molecular Immunology Center, Yangtze University, Jingzhou, 434023, China.
Department of Pharmacology, School of Basic Medicine, Health Science Center, Yangtze University, Jingzhou, 434023, China.
Curr Med Sci. 2023 Jun;43(3):434-444. doi: 10.1007/s11596-023-2727-4. Epub 2023 Apr 28.
Diabetes and its complications reduce quality of life and are life-limiting. At present, diabetes treatment consists of hypoglycemic agents to control blood glucose and the use of insulin-sensitizing drugs to overcome insulin resistance. In diabetes, autophagy is impaired and thus there is poor intracellular environment homeostasis. Pancreatic β-cells and insulin target tissues are protected by enhancing autophagy. Autophagy decreases β-cell apoptosis, promotes β-cell proliferation, and alleviates insulin resistance. Autophagy in diabetes is regulated by the mammalian target of rapamycin (mTOR)/adenosine 5'-monophosphate (AMP)-activated protein kinase (AMPK) pathway and others. Autophagy enhancers can likely be used as a treatment for diabetes and its complications. This review examines the evidence linking autophagy to diabetes.
糖尿病及其并发症降低了生活质量,且会危及生命。目前,糖尿病的治疗包括控制血糖的降血糖药物和使用胰岛素增敏药物来克服胰岛素抵抗。在糖尿病中,自噬受到损害,因此细胞内环境稳态不佳。通过增强自噬可以保护胰腺β细胞和胰岛素靶组织。自噬可减少β细胞凋亡,促进β细胞增殖,并减轻胰岛素抵抗。糖尿病中自噬受哺乳动物雷帕霉素靶蛋白(mTOR)/腺苷酸 5′-单磷酸(AMP)激活蛋白激酶(AMPK)途径等的调节。自噬增强剂可能可用于治疗糖尿病及其并发症。本文综述了自噬与糖尿病之间关联的证据。